Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249762 | 0.92 | HRH3 (0.49) | HRH3ADRA1AKCNH2 | |
| SCHEMBL10249721 | 0.90 | RAB9A (0.40) | HRH3RAB9ADRD3NPC1MAPK1 | |
| SCHEMBL13153287 | 0.86 | ESR1 (0.47) | RAB9ADRD3NPC1MAPK1ALDH1A1 | |
| SCHEMBL10252550 | 0.84 | HRH2 (0.42) | HRH3XDHKCNH2 | |
| SCHEMBL13151837 | 0.82 | GRIK2 (0.41) | MAPK1ALDH1A1HPGD | |
| SCHEMBL13152603 | 0.82 | MAPT (0.44) | MAPK1ALDH1A1HPGDSLC6A4 | |
| SCHEMBL13152111 | 0.82 | GRIK2 (0.38) | RAB9ANPC1MAPK1ALDH1A1HPGD | |
| SCHEMBL10097317 | 0.81 | LTA4H (0.48) | RAB9ANPC1SIGMAR1ALDH1A1SLC6A4 | |
| SCHEMBL12334400 | 0.81 | HRH3 (0.51) | HRH3ADRA1AKCNH2 | |
| SCHEMBL10097367 | 0.79 | HRH3 (0.44) | HRH3ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HRH3 976/4885RAB9A 3975/4885DRD3 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.